{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:39:48Z","timestamp":1769272788508,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Maxillofac Plast Reconstr Surg"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The rapidly developed vaccines against the severe acute respiratory syndrome coronavirus 2 carry a risk of provoking side effects. This study aimed to evaluate current vaccination non-serious\/serious side effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A multicenter electronic questionnaire via an online platform was conducted over a 1-week period among vaccinated dental staff and dental students inquiring whether they experienced vaccine-related side-effects after vaccine administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1205 respondents with a mean age of 39 (SD: 12) were retained for the analyses. The following vaccines were reported; Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV (Sinopharm). The majority of respondents received ChAdOx1 nCoV-19 (51.1%) and Gam-COVID-Vac (37.6%). The symptoms most frequently reported after vaccination were fatigue (79%), local pain in the injection site (77.4%), malaise (73%), and body pain (71.1%). Enrollees reported more onset of reactions on 0\u201312 h (44.1%) and 12\u201324 h (29.0%) after vaccine administration (<jats:italic>p<\/jats:italic> value &lt;0.001). In 75.7%, the side effects last for up to 3 days. Merely 5.5% of cases reported the presence of side effects after the first week. Individuals with a history of SARSCoV-2 and other infections (MERS, influenza, and EBV) were more likely to report a number of unserious systemic side effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The commonly reported adverse events were in line with similar studies. We have concerns with the frequency of serious adverse effects. This work necessitates the need for further clinical assessments with larger sample sizes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40902-021-00330-6","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T08:03:40Z","timestamp":1642061020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students\u2014which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?"],"prefix":"10.1186","volume":"44","author":[{"given":"Behzad","family":"Houshmand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seied Omid","family":"Keyhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid Reza","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1012-0730","authenticated-orcid":false,"given":"Shaqayeq","family":"Ramezanzade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erfan","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"330_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","volume":"91","author":"DS Hui","year":"2020","unstructured":"Hui DS, IA E, Madani TA, Ntoumi F, Kock R, Dar O et al. (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91:264\u2013266. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.009","journal-title":"Int J Infect Dis"},{"issue":"4","key":"330_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.34172\/aim.2020.02","volume":"23","author":"A Raoofi","year":"2020","unstructured":"Raoofi A, Takian A, Akbari Sari A, Olyaeemanesh A, Haghighi H, Aarabi M (2020) COVID-19 pandemic and comparative health policy learning in Iran. Arch Iran Med 23(4):220\u2013234","journal-title":"Arch Iran Med"},{"key":"330_CR3","unstructured":"Islamic Republic News Agency. https:\/\/en.irna.ir\/news\/84223480\/Iran-begins-COVID-19-vaccination. Accessed 15 May 2021"},{"key":"330_CR4","unstructured":"Islamic Republic News Agency. https:\/\/en.irna.ir\/news\/84233593\/Iran-issues-permit-for-emergency-use-for-three-other-COVID-19. Accessed 15 May 2021"},{"key":"330_CR5","unstructured":"Islamic Republic News Agency. https:\/\/en.irna.ir\/news\/84259871\/Iran-issues-permit-for-emergency-use-of-Sinopharm-vaccine. Accessed 15 May 2021"},{"key":"330_CR6","unstructured":"European Centre for Disease Prevention and Control. https:\/\/www.ecdc.europa.eu\/en\/geographical-distribution-2019-ncov-cases. Accessed 15 May 2021"},{"issue":"7","key":"330_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/trstmh\/traa140","volume":"115","author":"Z Barnett-Howell","year":"2021","unstructured":"Barnett-Howell Z, Watson OJ, Mobarak AM (2021) The benefits and costs of social distancing in high- and low-income countries. Trans R Soc Trop Med Hyg 115(7):807\u2013819. https:\/\/doi.org\/10.1093\/trstmh\/traa140","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"330_CR8","first-page":"12","volume":"42","author":"HR Fallahi","year":"2020","unstructured":"Fallahi HR, Keyhan SO, Zandian D, Kim SG, Cheshmi B (2020) Being a front-line dentist during the Covid-19 pandemic: a literature review. Maxillofac Plast Reconstr Surg 42:12","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"330_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/healthcare4030047","volume":"4","author":"HC Maltezou","year":"2016","unstructured":"Maltezou HC, Poland GA (2016) Immunization of health-care providers: necessity and public health policies. Healthcare (Basel) 4(3):47","journal-title":"Healthcare (Basel)"},{"issue":"10275","key":"330_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397(10275):671\u2013681. https:\/\/doi.org\/10.1016\/S0140-6736(21)00234-8","journal-title":"Lancet"},{"issue":"10269","key":"330_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"330_CR12","doi-asserted-by":"publisher","first-page":"n997","DOI":"10.1136\/bmj.n997","volume":"373","author":"K Thiagarajan","year":"2021","unstructured":"Thiagarajan K (2021) What do we know about India\u2019s Covaxin vaccine? BMJ 373:n997","journal-title":"BMJ"},{"key":"330_CR13","unstructured":"Reuters.com. https:\/\/www.reuters.com\/article\/health-coronavirus-china-vaccine-int-idUSKBN2940CA. Accessed 15 May 2021"},{"issue":"8","key":"330_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. (2021) First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep 70(8):283\u2013288. https:\/\/doi.org\/10.15585\/mmwr.mm7008e3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"330_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jamasurg.2021.0543","volume":"156","author":"SC Pitt","year":"2021","unstructured":"Pitt SC, Schwartz TA, Chu D (2021) AAPOR Reporting Guidelines for Survey Studies. JAMA Surg 156(8):785\u2013786","journal-title":"JAMA Surg"},{"key":"330_CR16","doi-asserted-by":"publisher","unstructured":"Pagotto V, Ferloni A, Soriano MM, Diaz M, Braguinsky N, Asprea V, et al. (2021) Active surveillance of the SPUTNIK V vaccine in health workers. medRxiv. https:\/\/doi.org\/10.1101\/2021.02.03.21251071.","DOI":"10.1101\/2021.02.03.21251071"},{"issue":"10267","key":"330_CR17","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. (2020) Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396(10267):1979\u20131993. https:\/\/doi.org\/10.1016\/S0140-6736(20)32466-1","journal-title":"Lancet"},{"issue":"7","key":"330_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 21(7):939\u2013949. https:\/\/doi.org\/10.1016\/S1473-3099(21)00224-3","journal-title":"Lancet Infect Dis."},{"issue":"7-8","key":"330_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00508-021-01835-w","volume":"133","author":"FX Heinz","year":"2021","unstructured":"Heinz FX, Stiasny K (2021) Profiles of current COVID-19 vaccines. Wien Klin Wochenschr 133(7-8):271\u2013283. https:\/\/doi.org\/10.1007\/s00508-021-01835-w","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"330_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis 21(7):950\u2013961","journal-title":"Lancet Infect Dis"},{"key":"330_CR21","doi-asserted-by":"publisher","unstructured":"Srivastava R, Ish P (2021) The initial experience of COVID-19 vaccination from a tertiary care centre of India. Monaldi Arch Chest Dis 91(4):1816. https:\/\/doi.org\/10.4081\/monaldi.2021.1816","DOI":"10.4081\/monaldi.2021.1816"},{"issue":"1","key":"330_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis 21(1):39\u201351. https:\/\/doi.org\/10.1016\/S1473-3099(20)30831-8","journal-title":"Lancet Infect Dis"},{"issue":"7855","key":"330_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41586-021-00998-w","volume":"592","author":"H Ledford","year":"2021","unstructured":"Ledford H (2021) COVID vaccines and blood clots: five key questions. Nature 592(7855):495\u2013496","journal-title":"Nature"},{"key":"330_CR24","doi-asserted-by":"publisher","unstructured":"Krammer F, Srivastava K, Simon V (2021) Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medRxiv. https:\/\/doi.org\/10.1101\/2021.01.29.21250653.","DOI":"10.1101\/2021.01.29.21250653"},{"key":"330_CR25","doi-asserted-by":"publisher","unstructured":"Saadat S, Rikhtegaran-Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al. (2021) Single dose vaccination in healthcare workers previously infected with SARS-CoV-2. MedRxiv. https:\/\/doi.org\/10.1101\/2021.01.30.21250843.","DOI":"10.1101\/2021.01.30.21250843"},{"key":"330_CR26","doi-asserted-by":"publisher","unstructured":"Chen T, Song J, Liu H, Zheng H, Chen C (2020) Positive epstein-barr virus detection in corona virus disease 2019 (covid-19) patients. Available at SSRN 3555268. https:\/\/doi.org\/10.2139\/ssrn.3555268.","DOI":"10.2139\/ssrn.3555268"}],"container-title":["Maxillofacial Plastic and Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40902-021-00330-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40902-021-00330-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40902-021-00330-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T08:04:12Z","timestamp":1642061052000},"score":1,"resource":{"primary":{"URL":"https:\/\/jkamprs.springeropen.com\/articles\/10.1186\/s40902-021-00330-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1186\/s40902-021-00330-6","relation":{},"ISSN":["2288-8586"],"issn-type":[{"value":"2288-8586","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed the American Association for Public Opinion Research (AAPOR) reporting guideline (Pitt et al. 2021), and the study protocol was registered at Shahid Beheshti University of Medical Sciences, with registration number IR.SBMU. RETECH. REC. 1400.164.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}